Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an 'Overweight' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowered the price target from $129 to $125.
August 04, 2023 | 9:19 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an 'Overweight' rating on Biomarin Pharmaceutical but lowered the price target from $129 to $125.
The news is directly related to Biomarin Pharmaceutical. While the 'Overweight' rating indicates a positive outlook, the lowering of the price target might have a neutralizing effect. The impact on the stock price in the short term is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100